Mostrando 10 resultados de: 25
Filtros aplicados
Publisher
Pharmacogenomics Journal(5)
Drug Metabolism and Drug Interactions(3)
Pharmacogenomics(3)
Expert Opinion on Drug Metabolism and Toxicology(2)
OMICS A Journal of Integrative Biology(2)
Área temáticas
Farmacología y terapéutica(18)
Bioquímica(9)
Medicina y salud(8)
Enfermedades(7)
Fisiología humana(5)
Área de conocimiento
Genética(17)
Farmacología(10)
Psicopatología(3)
Química analítica(2)
Laboratorio médico(1)
Origen
google(2)
Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusA combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
ArticleAbstract: This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combinatioPalabras claves:Autores:Adrián LLerena, Blasco-Fontecilla H., Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusABCB1 gene polymorphisms and violent suicide attempt among survivors
ArticleAbstract: Introduction: Those suicide attempters that choose violent methods dramatically diminish the possibiPalabras claves:ABCB1, Suicide attempt, Violent suicide methodsAutores:Adrián LLerena, Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 ethnic variability in hispanics
Book PartAbstract: Genetic polymorphism in the CYP2D6 gene results in a wide variability in CYP2D6 enzymatic activity,Palabras claves:Autores:Adrián LLerena, Dorado P., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 gene polymorphisms and pbkp_redicted phenotypes in eight indigenous groups from northwestern Mexico
ArticleAbstract: Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficienPalabras claves:allele frequency, CYP2D6polymorphism, Mexican indigenous, pbkp_redicted phenotype, pharmacogeneticsAutores:Adrián LLerena, Galaviz-Hernandez C., Garza-Veloz I., Lazalde-Ramos B.P., Martínez-Fierro M.L., Naranjo M.E.G., Sosa-Macías M.G.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusCYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
ArticleAbstract: Global precision medicine demands characterization of drug metabolism and phenotype variation in divPalabras claves:Biomarkers, developing world omics, drug metabolism variation, global personalized medicine, Systems DiagnosticsAutores:Adrián LLerena, de Andrés F., Naranjo M.E.G., Ramos B., Sosa-Macías M.G.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusErratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (Molecular Psychiatry (2013) 18 (266))
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Alonso E., Dorado P., Jung H., López-López M., Naranjo M.E.G., Ortega A., Penãs-Lledó E.M., Trejo H.D.Fuentes:scopus